Counter CM - Search Results

1

Rare codons capacitate Kras-driven de novo tumorigenesis.

Pershing NL, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, Counter CM. Pershing NL, et al. Among authors: counter cm. J Clin Invest. 2015 Jan;125(1):222-33. doi: 10.1172/JCI77627. Epub 2014 Dec 1. J Clin Invest. 2015. PMID: 25437878 Free PMC article.

2

Rare codons regulate KRas oncogenesis.

Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM. Lampson BL, et al. Among authors: counter cm. Curr Biol. 2013 Jan 7;23(1):70-5. doi: 10.1016/j.cub.2012.11.031. Epub 2012 Dec 13. Curr Biol. 2013. PMID: 23246410 Free PMC article.

3

Capturing the primordial Kras mutation initiating urethane carcinogenesis.

Li S, MacAlpine DM, Counter CM. Li S, et al. Among authors: counter cm. Nat Commun. 2020 Apr 14;11(1):1800. doi: 10.1038/s41467-020-15660-8. Nat Commun. 2020. PMID: 32286309 Free PMC article.

4

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.

Le Roux Ö, Pershing NLK, Kaltenbrun E, Newman NJ, Everitt JI, Baldelli E, Pierobon M, Petricoin EF, Counter CM. Le Roux Ö, et al. Among authors: counter cm. Elife. 2022 Sep 7;11:e75715. doi: 10.7554/eLife.75715. Elife. 2022. PMID: 36069770 Free PMC article.

5

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.

Weyandt JD, Lampson BL, Tang S, Mastrodomenico M, Cardona DM, Counter CM. Weyandt JD, et al. Among authors: counter cm. PLoS One. 2015 Oct 9;10(10):e0140253. doi: 10.1371/journal.pone.0140253. eCollection 2015. PLoS One. 2015. PMID: 26452271 Free PMC article.

6

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.

Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A, Counter CM, Wood KC. Ali M, et al. Among authors: counter cm. Nat Commun. 2017 Jun 8;8:15617. doi: 10.1038/ncomms15617. Nat Commun. 2017. PMID: 28593995 Free PMC article.

7

Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.

Pershing NL, Yang CFJ, Xu M, Counter CM. Pershing NL, et al. Among authors: counter cm. Oncotarget. 2016 Jul 5;7(27):42385-42392. doi: 10.18632/oncotarget.9874. Oncotarget. 2016. PMID: 27285753 Free PMC article.

8

Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway.

Peterson J, Li S, Kaltenbrun E, Erdogan O, Counter CM. Peterson J, et al. Among authors: counter cm. Sci Rep. 2020 Dec 17;10(1):22166. doi: 10.1038/s41598-020-78453-5. Sci Rep. 2020. PMID: 33335127 Free PMC article.

9

Targeting eNOS in pancreatic cancer.

Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, Counter CM. Lampson BL, et al. Among authors: counter cm. Cancer Res. 2012 Sep 1;72(17):4472-82. doi: 10.1158/0008-5472.CAN-12-0057. Epub 2012 Jun 27. Cancer Res. 2012. PMID: 22738914 Free PMC article.

10

RALA and RALBP1 regulate mitochondrial fission at mitosis.

Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM. Kashatus DF, et al. Among authors: counter cm. Nat Cell Biol. 2011 Aug 7;13(9):1108-15. doi: 10.1038/ncb2310. Nat Cell Biol. 2011. PMID: 21822277 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page